Mohs Surgery for Infiltrative Basal Cell Carcinoma

Introduction to Infiltrative BCC

Infiltrative basal cell carcinomas require Mohs micrographic surgery (MMS) as the treatment of choice due to their aggressive growth pattern, unpredictable subclinical extension, and significantly higher recurrence rates with standard excision, as recommended by the National Comprehensive Cancer Network 1, 2, 3

The American Academy of Dermatology explicitly recommends MMS for high-risk BCC, which includes all aggressive histologic subtypes like infiltrative BCC 2, 3
MMS achieves 5-year cure rates of 99% for primary BCC and 94.4% for recurrent disease, far superior to standard excision 4
Standard excision of high-risk tumors without complete margin assessment carries substantial risk, with one study showing 26.8% recurrence with positive margins versus 5.9% with negative margins 2, 3

Infiltrative BCCs are classified as "aggressive growth patterns" alongside micronodular, sclerosing, and morpheaform variants, all of which carry higher recurrence risk 1
Infiltrative BCC requires wider peripheral margins (5-10mm or more) even with standard excision, but even these margins may be insufficient without complete margin control 4
The British Journal of Dermatology guidelines state that recurrent tumors, especially on the face, are at high risk of further recurrence following surgical excision even with wide surgical margins 4

Refer for MMS immediately when infiltrative histology is confirmed on biopsy, as this is the standard of care for aggressive histologic subtypes 1, 2, 3
If MMS is unavailable, consider standard excision with frozen section control and wide margins (minimum 5-10mm), but understand this is a compromise with higher recurrence risk 4
Never use curettage and electrodesiccation for aggressive histologic subtypes, with reported recurrence rates of 19-27% even when mistakenly used 1